Drugs / APG-3288
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07424833 | Mar 2026 → Dec 2029 expected | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma +2 | Ascentage Pharma Group Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-02-05 | Ascentage Pharma Group Inc. | Regulatory Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 ascentage.com ↗
This IND clearance for APG-3288 in China will further strengthen the Company’s pipeline in hematologic malignancies and lay a strong foundation for potential combinations with other key assets within the pipeline. |
| 2026-01-14 | Ascentage Pharma Group Inc. | Regulatory Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference ascentage.com ↗
Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipeline |
| 2026-01-06 | Ascentage Pharma Group Inc. | Regulatory Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 ascentage.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-05 | Ascentage Pharma Group Inc. | Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 ascentage.com ↗ |
| 2026-01-14 | Ascentage Pharma Group Inc. | Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference ascentage.com ↗ |
| 2026-01-06 | Ascentage Pharma Group Inc. | Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 ascentage.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APG-3288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07424833 ↗ |
| Route | Oral | “Orally administered daily” NCT07424833 ↗ |